ABT Stock Analysis: Abbott Laboratories | NYSE
Medical Devices | NYSE, USA | Market Cap: 188.248m USD | 12M Return: -18.3% | US0028241000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 814M
EPS Trend: 98.7%
Qual. Beats: 1
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Abbott Laboratories (NYSE: ABT) is a diversified U.S. healthcare company headquartered in Abbott Park, Illinois, that discovers, develops, manufactures, and sells health care products worldwide. The company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its pharmaceutical offerings include generics for conditions such as pancreatic exocrine insufficiency, hypertension, dyslipidemia, migraine, and pain, along with anti-infectives and influenza vaccines. Its diagnostics segment spans immunoassay, clinical chemistry, hematology, molecular diagnostics, point-of-care testing, and rapid lateral flow tests for pathogens including HIV, SARS-CoV-2, influenza, RSV, and strep A. The nutritional segment provides pediatric and adult nutritional products and infant formula, while the medical devices segment covers cardiovascular rhythm management, electrophysiology, heart failure, vascular, and structural heart devices, as well as diabetes care (glucose monitoring systems) and neuromodulation devices.
Founded in 1888 as Abbott Alkaloidal Company and renamed in 1915, Abbott is classified within the GICS Health Care Equipment sub-industry and is a large-cap stock with a market capitalization of approximately $154.4 billion USD. The company has been publicly traded since 1978.
- FreeStyle Libre CGM sales accelerate double-digit diabetes growth
- Diagnostics revenue rebounds post-COVID as base testing normalizes
- Cardiovascular devices revenue lifted by structural heart demand
| Net Income: 5.42b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.08 > 1.0 |
| NWC/Revenue: 14.39% < 20% (prev 25.58%; Δ -11.20% < -1%) |
| CFO/TA 0.09 > 3% & CFO 9.90b > Net Income 5.42b |
| Net Debt (27.9b) to EBITDA (10.7b): 2.62 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.74b) vs 12m ago -0.46% < -2% |
| Gross Margin: 56.80% > 18% (prev 52.79%; Δ 4.02% > 0.5%) |
| Asset Turnover: 48.22% > 50% (prev 51.32%; Δ -3.10% > 0%) |
| Interest Coverage Ratio: 12.45 > 6 (EBIT TTM 7.93b / Interest Expense TTM 637.0m) |
| A: 0.06 (Total Current Assets 24.5b - Total Current Liabilities 17.8b) / Total Assets 109b |
| B: 0.46 (Retained Earnings 49.8b / Total Assets 109b) |
| C: 0.08 (EBIT TTM 7.93b / Avg Total Assets 96.6b) |
| D: 0.89 (Book Value of Equity 51.1b / Total Liabilities 57.5b) |
| Altman-Z'' = 3.37 = A |
| DSRI: 1.00 (Receivables 8.60b/7.97b, Revenue 46.6b/43.1b) |
| GMI: 0.93 (GM 52.79% / 56.80%) |
| AQI: 1.15 (AQ_t 0.66 / AQ_t-1 0.57) |
| SGI: 1.08 (Revenue 46.6b / 43.1b) |
| TATA: -0.04 (NI 5.42b - CFO 9.90b) / TA 109b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of September 09, 2026, the stock is trading at USD 105.52 with a total of 11,250,706 shares traded. Over the past week, the price has changed by -4.39%, over one month by -2.85%, over three months by +17.43% and over the past year by -18.34%.
Current recommended Stop Loss: 100.30 (which is 4.9% or 1.9 ATR below the current price).
Abbott Laboratories has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ABT.
- StrongBuy: 16
- Buy: 4
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 120.2 | 13.9% |
P/E Trailing = 35.6689
P/E Forward = 17.9856
P/S = 4.041
P/B = 3.6879
P/EG = 1.9989
Revenue TTM = 46.6b USD
EBIT TTM = 7.93b USD
EBITDA TTM = 10.7b USD
Long Term Debt = 9.90b USD (from longTermDebt, last fiscal year)
Short Term Debt = 3.00b USD (from shortTermDebt, last quarter)
Debt = 33.5b USD (from shortLongTermDebtTotal, last quarter) + Leases 931.0m
Net Debt = 27.9b USD (calculated: Debt 33.5b - CCE 5.60b)
Enterprise Value = 216b USD (188b + Debt 33.5b - CCE 5.60b)
Interest Coverage Ratio = 12.45 (Ebit TTM 7.93b / Interest Expense TTM 637.0m)
EV/FCF = 24.79x (Enterprise Value 216b / FCF TTM 8.72b)
FCF Yield = 4.03% (FCF TTM 8.72b / Enterprise Value 216b)
FCF Margin = 18.72% (FCF TTM 8.72b / Revenue TTM 46.6b)
Net Margin = 11.65% (Net Income TTM 5.42b / Revenue TTM 46.6b)
Gross Margin = 56.80% ((Revenue TTM 46.6b - Cost of Revenue TTM 20.1b) / Revenue TTM)
Gross Margin QoQ = 58.00% (prev 56.28%)
Tobins Q-Ratio = 1.98 (Enterprise Value 216b / Total Assets 109b)
Interest Expense / Debt = 1.90% (Interest Expense 637.0m / Debt 33.5b)
Taxrate = 27.77% (2.09b / 7.51b)
NOPAT = 5.73b (EBIT 7.93b * (1 - 27.77%))
Current Ratio = 1.38 (Total Current Assets 24.5b / Total Current Liabilities 17.8b)
Debt / Equity = 0.66 (Debt 33.5b / totalStockholderEquity, last quarter 51.1b)
Debt / EBITDA = 2.62 (Net Debt 27.9b / EBITDA 10.7b)
Debt / FCF = 3.20 (Net Debt 27.9b / FCF TTM 8.72b)
Total Stockholder Equity = 51.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.62% (Net Income 5.42b / Total Assets 109b)
RoE = 10.52% (Net Income TTM 5.42b / Total Stockholder Equity 51.6b)
RoCE = 12.91% (EBIT 7.93b / Capital Employed (Equity 51.6b + L.T.Debt 9.90b))
RoIC = 6.22% (NOPAT 5.73b / Invested Capital 92.1b)
WACC = 4.41% (E(188b)/V(222b) * Re(4.95%) + D(33.5b)/V(222b) * Rd(1.90%) * (1-Tc(0.28)))
Discount Rate = 4.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.03 | Cagr: -0.18%
[DCF] Terminal Value 77.97% ; FCFF base≈7.94b ; Y1≈9.10b ; Y5≈13.4b
[DCF] Fair Price = 100.4 (EV 202b - Net Debt 27.9b = Equity 174b / Shares 1.73b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.73 | EPS CAGR: 8.24% | SUE: 2.12 | # QB: 1
Revenue Correlation: 98.45 | Revenue CAGR: 5.64% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.42 | Chg30d=+0.16% | Revisions=-5% | Analysts=22
EPS current Year (2026-12-31): EPS=5.52 | Chg30d=+0.03% | Revisions=+73% | GrowthEPS=+7.2% | GrowthRev=+13.5%
EPS next Year (2027-12-31): EPS=6.06 | Chg30d=+0.04% | Revisions=+19% | GrowthEPS=+9.9% | GrowthRev=+8.6%
[Analyst] Revisions Ratio: +36% (up=40, down=18)